Impact of Different Types of Antiviral Therapy on Prognosis of Hepatitis C Virus Positive Marginal Zone Lymphomas

Abstract

almost overlapped beyond their anatomical sites. The miPD-L1-positive cases showed significantly better OS compared to the negative cases in both gastric and intestinal DLBCL (P=0.0430 and P=0.0115). DEL was found in 11 gastric (9%) and 6 intestinal cases (12%), with significantly worse OS than the others in each anatomical group (P=0.0012 and P=0.0008, respectively). Among patients with complete remission, 21 (16%) of 134 gastric and 6 (17%) of 36 intestinal DLBCL patients had recurrence. Differences in survival, calculated from recurrence, were significant between gastric DLBCL patients with and without POD24 (P=0.0427), but did not work in prognostic delineation of intestinal cases (P=0.563). Multivariate analysis revealed that advanced Lugano stage (P<0.001), DEL (P<0.001), and miPD-L1 negativity (<20%, P=0.027), but not intestinal site (P=0.171), were significant prognostic factors for OS of giDLBCL. Conclusion:The anatomical site of disease did not influence outcome in giDLBCL in the rituximab era. Lugano stage, PD-L1 expression on microenvironment immune cells, and MYC/BCL2 co-expression provide therapeutic guidance for patients with giDLBCL.